RecruitingPhase 1Phase 2NCT06924320

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

A Phase 1 Randomized, Double-Blind, Placebo Controlled. Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 Co-administered With MET097 in Adult Participants With Obesity or Overweight Including Participants With Type 2 Diabetes Mellitus

Sponsor

Metsera, a wholly owned subsidiary of Pfizer

Enrollment

132 participants

Start Date

Mar 3, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity and Obesity-related Medical Conditions

Summary

This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing two new experimental drugs — MET233 and MET097 — used together to help with weight loss in people who are overweight or have obesity, with or without type 2 diabetes. **You may be eligible if...** - Your BMI is between 27 and 38 - You are otherwise in good health (Parts A and B), OR you have well-controlled type 2 diabetes, high blood pressure, or high cholesterol (Part C) - If you have type 2 diabetes, it was diagnosed at least 3 months ago and your HbA1c (blood sugar control measure) is 10.5% or below **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your blood pressure is above 160/100 mmHg - You have a significant uncontrolled medical condition - You have a history of serious heart, liver, kidney, or gastrointestinal disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMET233 and MET097

For subcutaneous administration

DRUGPlacebo

Sterile 0.9% (w/v) saline for subcutaneous administration.

DRUGMET233

For subcutaneous administration

Locations(1)

Research Site MET233/097 24-101-001

Cypress, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06924320

Related Trials

Study of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity

NCT068999972 locations

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

NCT068944988 locations